Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Taipei City Hospital, Zhongxing Branch, Taipei, Taiwan.
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Arch Gerontol Geriatr. 2025 Jan;128:105596. doi: 10.1016/j.archger.2024.105596. Epub 2024 Jul 31.
Sarcopenia, characterized by age-related loss of muscle mass and function, poses a significant public health concern, particularly in Asia's rapidly aging population. This systematic review and meta-analysis aimed to evaluate the current epidemiology of sarcopenia in Asia using the 2019 Asian Working Group for Sarcopenia (AWGS) diagnostic criteria.
Databases including PubMed, Embase, Web of Science, and Cochrane were systematically searched for studies published until December 7, 2023, involving older adults aged ≥ 60 years diagnosed with sarcopenia using the 2019 AWGS criteria in Asia. Study quality was assessed, and meta-analyses were conducted to estimate the pooled prevalence of sarcopenia, possible sarcopenia, and severe sarcopenia.
A total of 140 studies, collectively involving 156,325 participants (67.1 % community-dwelling older adults with the minimum age for participant inclusion ranging from 60 to 80 years) from various Asian countries, were included. The overall prevalence of sarcopenia among community-dwelling older adults was 16.5 % (95 % CI: 14.7 %-18.4 %). Notably, the prevalence of possible sarcopenia was higher at 28.7 % (95 % CI: 22.0 %-36.5 %), while severe sarcopenia had a lower prevalence of 4.4 % (95 % CI: 3.3 %-5.8 %). Subgroup analyses revealed variations in sarcopenia prevalence based on diagnostic modalities, ranging from 7.5 % (95 % CI: 6.0 %-9.4 %) for assessments using bioelectrical impedance analysis, handgrip strength, gait speed, chair stand and short physical performance battery, to 20.8 % (95 % CI: 18.9 %-23.0 %) when using dual-energy X-ray absorptiometry coupled with muscle strength and physical performance measures.
This comprehensive systematic review and meta-analysis highlights the substantial burden of sarcopenia among older adults in Asia, underscoring the need for early identification and intervention strategies to mitigate its adverse consequences on public health.
肌少症是一种与年龄相关的肌肉质量和功能丧失的特征，对公共健康构成了重大威胁，特别是在亚洲人口迅速老龄化的地区。本系统评价和荟萃分析旨在使用 2019 年亚洲肌少症工作组（AWGS）的诊断标准，评估亚洲肌少症的当前流行病学。
系统检索了 PubMed、Embase、Web of Science 和 Cochrane 数据库，检索截至 2023 年 12 月 7 日发表的研究，这些研究涉及在亚洲使用 2019 年 AWGS 标准诊断为肌少症的年龄≥60 岁的老年人。评估了研究质量，并进行荟萃分析以估计肌少症、可能肌少症和严重肌少症的 pooled 患病率。
共纳入了 140 项研究，共涉及来自亚洲各国的 156325 名参与者（67.1%为社区居住的老年人，纳入参与者的最小年龄范围为 60-80 岁）。社区居住的老年人肌少症的总体患病率为 16.5%（95%CI：14.7%-18.4%）。值得注意的是，可能肌少症的患病率更高，为 28.7%（95%CI：22.0%-36.5%），而严重肌少症的患病率较低，为 4.4%（95%CI：3.3%-5.8%）。亚组分析显示，根据诊断方法，肌少症的患病率存在差异，从生物电阻抗分析、握力、步速、椅子站立和简短体能测试的评估中为 7.5%（95%CI：6.0%-9.4%），到使用双能 X 射线吸收法与肌肉力量和体能测试相结合时为 20.8%（95%CI：18.9%-23.0%）。
本系统评价和荟萃分析全面总结了亚洲老年人肌少症的巨大负担，强调了早期识别和干预策略的必要性，以减轻其对公共健康的不良后果。
